Full width home advertisement

Welcome Home


Post Page Advertisement [Top]

The Moderna COVID-19 Vaccine Remains Highly Effective 5 Months After the Second Dose

 



Research conducted by Kaiser Permanente in Southern California and published on November 25, 2021 in The Lancet Regional Health – Americas confirmed that the Moderna COVID-19 vaccine was highly effective for up to 5 months after the second dose. When it came to COVID-19 infection, the effectiveness was 87 percent, hospitalization was 96 percent, and death was 98 percent, respectively.

 

In a statement, Katia Bruxvoort, PhD, an adjunct investigator with Kaiser Permanente Southern California's Department of Research and Evaluation said, "This study provides reassuring evidence of the Moderna COVID-19 vaccine's high efficacy in preventing COVID-19 infection, hospitalization, and death." In addition to including more than 700,000 adults from a diverse range of racial and ethnic backgrounds, the study included participants with a wide range of underlying medical conditions, including chronic diseases, immunocompromising conditions, and autoimmune conditions.

 

Moderna COVID-19 mRNA vaccine was evaluated in a 5-year observational study conducted at Kaiser Permanente, a Southern California-based integrated health care organization with 4.7 million members. The vaccine was found to be effective for 5 months after administration.

 

The study included 352,878 participants who received two doses of the Moderna COVID-19 vaccine and were matched by age, gender, race, and ethnicity to a control group of 352,878 individuals who had not been vaccinated. Individuals who received two doses of the Moderna COVID-19 vaccine between December 18, 2020, and March 31, 2021, were considered vaccinees. Until June 30, 2021, both groups of individuals were observed and recorded.

 

  • COVID-19 infections occurred during follow-up in 289 patients who had been vaccinated and 1,144 patients who had not been vaccinated. The vaccine was found to be 87 percent effective against COVID-19 infection in laboratory animals.
  • Thirteen vaccinated patients were admitted to the hospital and 182 unvaccinated patients were admitted to the hospital, and one vaccinated patient was admitted to the hospital and 25 unvaccinated patients died from COVID-19. It was found that the vaccine was 96 percent effective in preventing COVID-19 hospitalization and 98 percent effective in preventing COVID-19 hospital deaths.
  • The effectiveness of the vaccine against COVID-19 infection was consistent across age, gender, race, and ethnic subgroups, with rates ranging from 83 to 92 percent.
  • Symptomatic COVID-19 (88 percent) was more resistant to the vaccine compared to asymptomatic COVID-19 (73 percent ).
  • Between March and June of this year, a total of 5,619 SARS-CoV-2 positive specimens were successfully sequenced. The most common variants were alpha (42 percent), epsilon (18 percent), delta (12 percent), and gamma (9 percent), with delta increasing to 54 percent of all variants by June 2021.

 

In a statement, Hung Fu Tseng, PhD, a researcher with Kaiser Permanente Southern California's Department of Research and Evaluation and the study's senior author, said, "This study adds to the body of evidence regarding the effectiveness of the Moderna COVID-19 vaccine in the real world, particularly in the general population." "Besides that, we followed these fully vaccinated patients until June 2021, which coincided with the emergence of the delta variant in the United States of America. A long-term follow-up is being carried out in order to determine the durability of the protection."


No comments:

Post a Comment

Bottom Ad [Post Page]